NovoCure Limited (NASDAQ: NVCR) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare NovoCure Limited to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, profitability, earnings, dividends and valuation.
This table compares NovoCure Limited and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NovoCure Limited Competitors||-4,766.74%||-354.83%||-43.39%|
Earnings & Valuation
This table compares NovoCure Limited and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|NovoCure Limited||$125.17 million||-$69.14 million||-18.77|
|NovoCure Limited Competitors||$464.68 million||$167.54 million||-6.57|
NovoCure Limited’s rivals have higher revenue and earnings than NovoCure Limited. NovoCure Limited is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
36.8% of NovoCure Limited shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.7% of NovoCure Limited shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for NovoCure Limited and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NovoCure Limited Competitors||1377||4466||12285||311||2.63|
NovoCure Limited presently has a consensus price target of $20.14, indicating a potential downside of 2.46%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.50%. Given NovoCure Limited’s rivals higher probable upside, analysts plainly believe NovoCure Limited has less favorable growth aspects than its rivals.
Risk & Volatility
NovoCure Limited has a beta of 4.42, suggesting that its stock price is 342% more volatile than the S&P 500. Comparatively, NovoCure Limited’s rivals have a beta of 6.57, suggesting that their average stock price is 557% more volatile than the S&P 500.
NovoCure Limited rivals beat NovoCure Limited on 7 of the 12 factors compared.
NovoCure Limited Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.